1
|
Cuadrado-Tejedor M, Garcia-Barroso C, Sanzhez-Arias J, Mederos S, Rabal O, Ugarte A, Franco R, Pascual-Lucas M, Segura V, Perea G, Oyarzabal J, Garcia-Osta A. Concomitant histone deacetylase and phosphodiesterase 5 inhibition synergistically prevents the disruption in synaptic plasticity and it reverses cognitive impairment in a mouse model of Alzheimer's disease. Clin Epigenetics 2015; 7:108. [PMID: 26457123 PMCID: PMC4599811 DOI: 10.1186/s13148-015-0142-9] [Citation(s) in RCA: 46] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2015] [Accepted: 09/28/2015] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Given the implication of histone acetylation in memory processes, histone deacetylase inhibitors (HDACIs) have been postulated as potential modulators of cognitive impairment in Alzheimer's disease (AD). However, dose-dependent side effects have been described in patients with the currently available broad-spectrum HDACIs, explaining why their therapeutic potential has not been realized for chronic diseases. Here, by simultaneously targeting two independent enzyme activities, histone deacetylase (HDAC) and phosphodiesterase-5 (PDE5), we propose a novel mode of inhibitory action that might increase the therapeutic specificity of HDACIs. RESULTS The combination of vorinostat, a pan-HDACI, and tadalafil, a PDE5 inhibitor, rescued the long-term potentiation impaired in slices from APP/PS1 mice. When administered in vivo, the combination of these drugs alleviated the cognitive deficits in AD mice, as well as the amyloid and tau pathology, and it reversed the reduced dendritic spine density on hippocampal neurons. Significantly, the combination of vorinostat and tadalafil was more effective than each drug alone, both against the symptoms and in terms of disease modification, and importantly, these effects persisted after a 4-week washout period. CONCLUSIONS The results highlight the pharmacological potential of a combination of molecules that inhibit HDAC and PDE5 as a therapeutic approach for AD treatment.
Collapse
Affiliation(s)
- M Cuadrado-Tejedor
- Neurobiology of Alzheimer's Disease, Neurosciences Division, Center for Applied Medical Research (CIMA), University of Navarra, Pio XII, 31008 Pamplona, Spain.,Anatomy Department, School of Medicine, University of Navarra, Pamplona, Spain
| | - C Garcia-Barroso
- Neurobiology of Alzheimer's Disease, Neurosciences Division, Center for Applied Medical Research (CIMA), University of Navarra, Pio XII, 31008 Pamplona, Spain
| | - J Sanzhez-Arias
- Small Molecule Discovery Platform, Molecular Therapeutics Program, Center for Applied Medical Research (CIMA), University of Navarra, Pio XII, 55, 31008 Pamplona, Spain
| | - S Mederos
- Cajal Institute, CSIC, Madrid, Spain
| | - O Rabal
- Small Molecule Discovery Platform, Molecular Therapeutics Program, Center for Applied Medical Research (CIMA), University of Navarra, Pio XII, 55, 31008 Pamplona, Spain
| | - A Ugarte
- Small Molecule Discovery Platform, Molecular Therapeutics Program, Center for Applied Medical Research (CIMA), University of Navarra, Pio XII, 55, 31008 Pamplona, Spain
| | - R Franco
- Neurobiology of Alzheimer's Disease, Neurosciences Division, Center for Applied Medical Research (CIMA), University of Navarra, Pio XII, 31008 Pamplona, Spain.,Department of Biochemistry and Molecular Biology, Faculty of Biology, University of Barcelona, Barcelona, Spain
| | - M Pascual-Lucas
- Neurobiology of Alzheimer's Disease, Neurosciences Division, Center for Applied Medical Research (CIMA), University of Navarra, Pio XII, 31008 Pamplona, Spain
| | - V Segura
- Bioinformatics Unit, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain
| | - G Perea
- Cajal Institute, CSIC, Madrid, Spain
| | - J Oyarzabal
- Small Molecule Discovery Platform, Molecular Therapeutics Program, Center for Applied Medical Research (CIMA), University of Navarra, Pio XII, 55, 31008 Pamplona, Spain
| | - A Garcia-Osta
- Neurobiology of Alzheimer's Disease, Neurosciences Division, Center for Applied Medical Research (CIMA), University of Navarra, Pio XII, 31008 Pamplona, Spain
| |
Collapse
|
2
|
Pascual-Lucas M, Viana da Silva S, Di Scala M, Garcia-Barroso C, González-Aseguinolaza G, Mulle C, Alberini CM, Cuadrado-Tejedor M, Garcia-Osta A. Insulin-like growth factor 2 reverses memory and synaptic deficits in APP transgenic mice. EMBO Mol Med 2015; 6:1246-62. [PMID: 25100745 PMCID: PMC4287930 DOI: 10.15252/emmm.201404228] [Citation(s) in RCA: 102] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
Insulin-like growth factor 2 (IGF2) was recently found to play a critical role in memory consolidation in rats and mice, and hippocampal or systemic administration of recombinant IGF2 enhances memory. Here, using a gene therapy-based approach with adeno-associated virus (AAV), we show that IGF2 overexpression in the hippocampus of aged wild-type mice enhances memory and promotes dendritic spine formation. Furthermore, we report that IGF2 expression decreases in the hippocampus of patients with Alzheimer's disease, and this leads us to hypothesize that increased IGF2 levels may be beneficial for treating the disease. Thus, we used the AAV system to deliver IGF2 or IGF1 into the hippocampus of the APP mouse model Tg2576 and demonstrate that IGF2 and insulin-like growth factor 1 (IGF1) rescue behavioural deficits, promote dendritic spine formation and restore normal hippocampal excitatory synaptic transmission. The brains of Tg2576 mice that overexpress IGF2 but not IGF1 also show a significant reduction in amyloid levels. This reduction probably occurs through an interaction with the IGF2 receptor (IGF2R). Hence, IGF2 and, to a lesser extent, IGF1 may be effective treatments for Alzheimer's disease.
Collapse
Affiliation(s)
- Maria Pascual-Lucas
- Neurosciences Division, Center for Applied Medical Research, CIMA University of Navarra, Pamplona, Spain
| | - Silvia Viana da Silva
- Interdisciplinary Institute for Neuroscience, Université of Bordeaux CNRS UMR 5297, Bordeaux, France
| | - Marianna Di Scala
- Gene Therapy and Hepatology Division, Center for Applied Medical Research CIMA University of Navarra, Pamplona, Spain
| | - Carolina Garcia-Barroso
- Neurosciences Division, Center for Applied Medical Research, CIMA University of Navarra, Pamplona, Spain
| | - Gloria González-Aseguinolaza
- Gene Therapy and Hepatology Division, Center for Applied Medical Research CIMA University of Navarra, Pamplona, Spain
| | - Christophe Mulle
- Interdisciplinary Institute for Neuroscience, Université of Bordeaux CNRS UMR 5297, Bordeaux, France
| | | | - Mar Cuadrado-Tejedor
- Neurosciences Division, Center for Applied Medical Research, CIMA University of Navarra, Pamplona, Spain Department of Anatomy, School of Medicine University of Navarra, Pamplona, Spain
| | - Ana Garcia-Osta
- Neurosciences Division, Center for Applied Medical Research, CIMA University of Navarra, Pamplona, Spain
| |
Collapse
|
3
|
Cochoy DM, Kolevzon A, Kajiwara Y, Schoen M, Pascual-Lucas M, Lurie S, Buxbaum JD, Boeckers TM, Schmeisser MJ. Phenotypic and functional analysis of SHANK3 stop mutations identified in individuals with ASD and/or ID. Mol Autism 2015; 6:23. [PMID: 26045941 PMCID: PMC4455919 DOI: 10.1186/s13229-015-0020-5] [Citation(s) in RCA: 52] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2015] [Accepted: 04/17/2015] [Indexed: 12/12/2022] Open
Abstract
BACKGROUND SHANK proteins are crucial for the formation and plasticity of excitatory synapses. Although mutations in all three SHANK genes are associated with autism spectrum disorder (ASD), SHANK3 appears to be the major ASD gene with a prevalence of approximately 0.5% for SHANK3 mutations in ASD, with higher rates in individuals with ASD and intellectual disability (ID). Interestingly, the most relevant mutations are typically de novo and often are frameshift or nonsense mutations resulting in a premature stop and a truncation of SHANK3 protein. METHODS We analyzed three different SHANK3 stop mutations that we identified in individuals with ASD and/or ID, one novel (c.5008A > T) and two that we recently described (c.1527G > A, c.2497delG). The mutations were inserted into the human SHANK3a sequence and analyzed for effects on subcellular localization and neuronal morphology when overexpressed in rat primary hippocampal neurons. RESULTS Clinically, all three individuals harboring these mutations had global developmental delays and ID. In our in vitro assay, c.1527G > A and c.2497delG both result in proteins that lack most of the SHANK3a C-terminus and accumulate in the nucleus of transfected cells. Cells expressing these mutants exhibit converging morphological phenotypes including reduced complexity of the dendritic tree, less spines, and less excitatory, but not inhibitory synapses. In contrast, the truncated protein based on c.5008A > T, which lacks only a short part of the sterile alpha motif (SAM) domain in the very SHANK3a C-terminus, does not accumulate in the nucleus and has minor effects on neuronal morphology. CONCLUSIONS In spite of the prevalence of SHANK3 disruptions in ASD and ID, only a few human mutations have been functionally characterized; here we characterize three additional mutations. Considering the transcriptional and functional complexity of SHANK3 in healthy neurons, we propose that any heterozygous stop mutation in SHANK3 will lead to a dysequilibrium of SHANK3 isoform expression and alterations in the stoichiometry of SHANK3 protein complexes, resulting in a distinct perturbation of neuronal morphology. This could explain why the clinical phenotype in all three individuals included in this study remains quite severe - regardless of whether there are disruptions in one or more SHANK3 interaction domains.
Collapse
Affiliation(s)
- Daniela M Cochoy
- Institute for Anatomy and Cell Biology, Ulm University, Albert-Einstein-Allee 11, D-89081 Ulm, Germany
| | - Alexander Kolevzon
- Seaver Autism Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029 USA ; Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029 USA ; Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029 USA ; Department of Psychiatry, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029 USA ; Department of Pediatrics, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029 USA
| | - Yuji Kajiwara
- Department of Psychiatry, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029 USA
| | - Michael Schoen
- Institute for Anatomy and Cell Biology, Ulm University, Albert-Einstein-Allee 11, D-89081 Ulm, Germany
| | - Maria Pascual-Lucas
- Institute for Anatomy and Cell Biology, Ulm University, Albert-Einstein-Allee 11, D-89081 Ulm, Germany ; Neuroscience Division, Center for Applied Medical Research, CIMA, University of Navarra, Av. Pio XII 55, 31008 Pamplona, Spain
| | - Stacey Lurie
- Seaver Autism Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029 USA ; Department of Psychiatry, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029 USA
| | - Joseph D Buxbaum
- Seaver Autism Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029 USA ; Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029 USA ; Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029 USA ; Department of Psychiatry, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029 USA ; Department of Neuroscience, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029 USA ; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029 USA
| | - Tobias M Boeckers
- Institute for Anatomy and Cell Biology, Ulm University, Albert-Einstein-Allee 11, D-89081 Ulm, Germany
| | - Michael J Schmeisser
- Institute for Anatomy and Cell Biology, Ulm University, Albert-Einstein-Allee 11, D-89081 Ulm, Germany
| |
Collapse
|
4
|
Wrzosek M, Lukaszkiewicz J, Jakubczyk A, Wrzosek M, Matsumoto H, Wojnar M, Lee J, Lee B, Choi M, Chai Y, Choi I, Janu L, Rackova S, Horacek J, Sanchez-Catalan M, Hipolito L, Marti-Prats L, Orrico A, Zornoza T, Granero L, Polache A, Marti-Prats L, Sanchez-Catalan M, Orrico A, Hipolito L, Zornoza T, Polache A, Granero L, Sanchez-Catalan M, Marti-Prats L, Hipolito L, Orrico A, Zornoza T, Granero L, Polache A, Milivojevic V, Kranzler HR, Covault J, Glahn A, Wenzel C, Wilhelm J, Frieling H, Heberlein A, Bleich S, Hillemacher T, Colombo G, Lobina C, Carai MAM, Gessa G, Cacciaglia R, Loche A, Kuthcer E, Egorov A, Filatova E, Kulagina K, Filatova EV, Kuther E, Kulagina K, Egorov AY, Loi B, Lobina C, Maccioni P, Carai MAM, Gessa G, Colombo G, Ledesma J, Aragon CMG, Quoilin C, Didone V, Quertemont E, Kemppainen H, Raivio N, Kiianmaa K, Pascual-Mora M, Couto BRD, Minarro J, Guerri C, Alfonso-Loeches S, Pascual-Mora M, Urena-Peralta J, Pascual-Lucas M, Morillo MJ, Renau-Piqueras J, Guerri C, Marin M, Esteban-Pretel G, Ponsoda X, Romero A, Ballestin R, Lopez C, Megias L, Timoneda J, Molowni A, Renau-Piqueras J, Escrig MA, Aragon CMG, Raivio N, Tiraboschi E, Saarikoski ST, Castren E, Kiianmaa K, Tarragon E, Balino P, Aragon CM, Camarini R, Soares SL, Carrara-Nascimento PF, Godinho RO, Scavone C, Tarragon E, Aragon CM, Balino P, Aragon CM, Kanuri G, Kreusch F, Quertement E, Closon C, Didone V, Masson S, Seutin V, Quertemont E, Durazzo TC, Fryer SL, Hutchison KE, Mon A, Meyerhoff DJ, Nummi KP, Salaspuro M, Vakevainen S, Ukai W, Shirasaka T, Hashimoto E, Yoshinaga T, Kaneta H, Kigawa M, Igarashi T, Watanabe K, Tateno M, Ishii T, Saito T, Lallemand F, Ward RJ, De Witte P, Verbank P, Fiore M, Ceccanti M, Ceccanti M. POSTER SESSION 1: BASIC RESEARCH AND INTERNAL MEDICINE * BASIC RESEARCH * P01 * ASSOCIATION BETWEEN FOK I VITAMIN D RECEPTOR (VDR) GENE POLYMORPHISM AND IMPULSIVENESS IN ALCOHOL-DEPENDENT PATIENTS. Alcohol Alcohol 2011. [DOI: 10.1093/alcalc/agr117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|